This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation CAR & T Cell Therapies
March 11-14, 2024 | Part of BPI West
Town and Country ResortSan Diego, CA

Catherine Sanders, PhD
VP, Research and Business Development at Adaptive Biotechnologies


Catherine Sanders, PhD, M.S, is Vice President, Research and Business Development at Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. With more than 10 years at the company and vast expertise in the field of immunosequencing, Catherine is responsible for establishing partnerships with pharmaceutical companies and collaborations with key opinion leaders in oncology, hematology, transplantation, infectious disease and autoimmunity to drive therapeutic development. Catherine began her career as a post-doctoral fellow at the HudsonAlpha Institute for Biotechnology analyzing immune repertoire changes in cancer, autoimmune disease, and infectious disease. She received a Ph.D. in immunopathology and a M.S. in pathology from the University of Mississippi Medical Center in Jackson where she focused on TLR, chemokine receptor, and cytokine expression in HIV-infected T lymphocyte subsets. Catherine also holds a BS degree in Medical Technology from Mississippi State University and received her board certification from Vanderbilt University Medical Center.